119 related articles for article (PubMed ID: 37022356)
41. The life-threatening eruptions of immune checkpoint inhibitor therapy.
Coleman EL; Olamiju B; Leventhal JS
Clin Dermatol; 2020; 38(1):94-104. PubMed ID: 32197753
[TBL] [Abstract][Full Text] [Related]
42. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
43. Immunohistopathological Findings of Severe Cutaneous Adverse Drug Reactions.
Orime M
J Immunol Res; 2017; 2017():6928363. PubMed ID: 29226159
[TBL] [Abstract][Full Text] [Related]
44. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.
Ellis SR; Vierra AT; Millsop JW; Lacouture ME; Kiuru M
J Am Acad Dermatol; 2020 Oct; 83(4):1130-1143. PubMed ID: 32360716
[TBL] [Abstract][Full Text] [Related]
45. High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer.
Kuo AM; Markova A
Front Med (Lausanne); 2022; 9():898790. PubMed ID: 35770005
[TBL] [Abstract][Full Text] [Related]
46. Differential diagnosis of severe cutaneous drug eruptions.
Bachot N; Roujeau JC
Am J Clin Dermatol; 2003; 4(8):561-72. PubMed ID: 12862499
[TBL] [Abstract][Full Text] [Related]
47. Cutaneous Hypersensitivity Reactions to Immune Checkpoint Inhibitors.
Storgard R; Markova A
J Allergy Clin Immunol Pract; 2024 May; 12(5):1132-1136. PubMed ID: 38548170
[TBL] [Abstract][Full Text] [Related]
48. Treatments for Severe Cutaneous Adverse Reactions.
Cho YT; Chu CY
J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
[TBL] [Abstract][Full Text] [Related]
49. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
50. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
51. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
52. Clinical presentation and management of atypical and recalcitrant acute generalized exanthematous pustulosis.
Hadavand MA; Kaffenberger B; Cartron AM; Trinidad JCL
J Am Acad Dermatol; 2022 Sep; 87(3):632-639. PubMed ID: 32926975
[TBL] [Abstract][Full Text] [Related]
53. Management of immune checkpoint inhibitor-related dermatologic adverse events.
Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
[TBL] [Abstract][Full Text] [Related]
54. Toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Orphanet J Rare Dis; 2010 Dec; 5():39. PubMed ID: 21162721
[TBL] [Abstract][Full Text] [Related]
55. The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.
Pach J; Valido K; Belzer A; Leventhal JS
Am J Clin Dermatol; 2024 Jul; 25(4):595-607. PubMed ID: 38767827
[TBL] [Abstract][Full Text] [Related]
56. Severe Drug Hypersensitivity Reactions: Clinical Pattern, Diagnosis, Etiology and Therapeutic Options.
Paulmann M; Mockenhaupt M
Curr Pharm Des; 2016; 22(45):6852-6861. PubMed ID: 27779083
[TBL] [Abstract][Full Text] [Related]
57. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome.
Harr T; French LE
Med Clin North Am; 2010 Jul; 94(4):727-42, x. PubMed ID: 20609860
[TBL] [Abstract][Full Text] [Related]
58. Severe Cutaneous Adverse Drug Reactions: Presentation, Risk Factors, and Management.
Mustafa SS; Ostrov D; Yerly D
Curr Allergy Asthma Rep; 2018 Mar; 18(4):26. PubMed ID: 29574562
[TBL] [Abstract][Full Text] [Related]
59. Drug Hypersensitivity Reactions.
Wilkerson RG
Immunol Allergy Clin North Am; 2023 Aug; 43(3):473-489. PubMed ID: 37394254
[TBL] [Abstract][Full Text] [Related]
60. Stevens-Johnson syndrome and toxic epidermal necrolysis: clinical patterns, diagnostic considerations, etiology, and therapeutic management.
Mockenhaupt M
Semin Cutan Med Surg; 2014 Mar; 33(1):10-6. PubMed ID: 25037254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]